Contact Us
Global Focal Segmental Glomerulosclerosis Market Report 2025

Focal Segmental Glomerulosclerosis Global Market Report 2025 - By Disease Type (Primary Focal Segmental Glomerulosclerosis, Secondary Focal Segmental Glomerulosclerosis), By Treatment (Drug Therapy, Dialysis, Kidney Transplant, Other Treatments), By Drug Class (Immunosuppressants, Angiotensin Inhibitors, Corticosteroids), By Route Of Administration (Oral, Parenteral), By End User (Hospitals, Homecare, Specialty Clinics, Other End Users) - Market Size, Trends, And Global Forecast 2025-2034

Focal Segmental Glomerulosclerosis Global Market Report 2025

Report Price : $4490.00 | Pages : 200 | Published : June 2025 | Delivery Time: 2-3 business days Info icon | Format : pdf icon

Need assistance or more information before the purchase?

Enquire Before Buying
Focal Segmental Glomerulosclerosis Global Market Report 2025

Proud Members Of

checkslacipN checkaoirsN checkscipN

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

What Is Covered Under Focal Segmental Glomerulosclerosis Market?

Focal segmental glomerulosclerosis (FSGS) is a rare kidney disorder marked by scarring (sclerosis) in segments of some glomeruli, the kidney’s filtering units, resulting in proteinuria and progressive kidney damage. It plays a key role in clinical diagnosis and research aimed at understanding proteinuria-related kidney diseases and developing targeted therapies to prevent kidney failure.

The main disease types of focal segmental glomerulosclerosis are primary focal segmental glomerulosclerosis and secondary focal segmental glomerulosclerosis. Primary focal segmental glomerulosclerosis (FSGS) is a kidney disorder characterized by scarring (sclerosis) in scattered regions (focal) of some glomeruli (segmental), leading to proteinuria and progressive loss of kidney function without a known secondary cause. Treatment options include drug therapy, dialysis, kidney transplantation, and others, with drug classes used being immunosuppressants, angiotensin inhibitors, and corticosteroids. These medications are administered via oral and parenteral routes and are managed across various end-user settings, including hospitals, homecare environments, specialty clinics, and others.

Focal Segmental Glomerulosclerosis Market Size and growth rate 2025 to 2029: Graph

What Is The Focal Segmental Glomerulosclerosis Market Size 2025 And Growth Rate?

The focal segmental glomerulosclerosis market size has grown strongly in recent years. It will grow from $1.46 billion in 2024 to $1.57 billion in 2025 at a compound annual growth rate (CAGR) of 7.6%. The growth in the historic period can be attributed to increasing prevalence of chronic kidney diseases, rising awareness about kidney disorders, increasing incidence of end-stage renal disease, increasing investment in research and development, and rising geriatric population.

What Is The Focal Segmental Glomerulosclerosis Market Growth Forecast?

The focal segmental glomerulosclerosis market size is expected to see strong growth in the next few years. It will grow to $2.09 billion in 2029 at a compound annual growth rate (CAGR) of 7.3%. The growth in the forecast period can be attributed to a growing number of clinical trials, increasing healthcare infrastructure improvements, rising demand for personalized medicine, growing availability and accessibility of immunosuppressive drugs, and rising demand for tailored therapeutic interventions. Major trends in the forecast period include advancements in genetic research, integration of precision medicine, technology innovations in diagnostic tools, developments in immunosuppressive drug formulations, and advancements in biomarker identification.

How Is The Focal Segmental Glomerulosclerosis Market Segmented?

The focal segmental glomerulosclerosis market covered in this report is segmented –

1) By Disease Type: Primary Focal Segmental Glomerulosclerosis, Secondary Focal Segmental Glomerulosclerosis

2) By Treatment: Drug Therapy, Dialysis, Kidney Transplant, Other Treatments

3) By Drug Class: Immunosuppressants, Angiotensin Inhibitors, Corticosteroids

4) By Route Of Administration: Oral, Parenteral

5) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users

Subsegments:

1) By Primary Focal Segmental Glomerulosclerosis: Idiopathic Focal Segmental Glomerulosclerosis, Genetic Or Familial Focal Segmental Glomerulosclerosis, Collapsing Variant, Tip Lesion Variant, Cellular Variant, Perihilar Variant

2) By Secondary Focal Segmental Glomerulosclerosis: Virus-Associated Focal Segmental Glomerulosclerosis, Drug-Induced Focal Segmental Glomerulosclerosis, Adaptive Or Compensatory Focal Segmental Glomerulosclerosis, Other Secondary Causes

What Is Driving The Focal Segmental Glomerulosclerosis Market? The Rise In Kidney Diseases Fuels The Growth Of The Market Due To Increasing Incidence From Diabetes And CKD Mortality Trends

The rising prevalence of kidney diseases is expected to propel the growth of the focal segmental glomerulosclerosis market going forward. Kidney diseases refer to conditions that impair the function and structure of the kidneys, affecting their ability to filter waste, balance fluids, and regulate essential body functions. The rising prevalence of kidney diseases is primarily due to diabetes, as high blood sugar levels over time damage the kidneys' filtering units, leading to diabetic nephropathy. Focal segmental glomerulosclerosis highlights the progressive scarring of kidney filters, serving as a critical indicator and target for understanding, diagnosing, and managing chronic kidney diseases. For instance, in December 2024, according to the Australian Institute of Health and Welfare, an Australia-based government agency, chronic kidney disease (CKD) mortality rates experienced a year-on-year increase in both 2021 and 2022, rising by 4.2% and 6.2%, respectively. Therefore, the rising prevalence of kidney diseases is driving the focal segmental glomerulosclerosis market.

Who Are The Major Players In The Global Focal Segmental Glomerulosclerosis Market?

Major companies operating in the focal segmental glomerulosclerosis market are Pfizer Inc., Merck And Co. Inc., Sanofi S.A., Eli Lilly and Company, Boehringer Ingelheim GmbH, Astellas Pharma Inc., Vertex Pharmaceuticals Incorporated, Mallinckrodt ARD LLC, Kyowa Kirin Co. Ltd., Aurinia Pharmaceuticals Inc., Travere Therapeutics Inc., Eledon Pharmaceuticals Inc., ZyVersa Therapeutics Inc., Complexa Inc., Certa Therapeutics, Delta 4 GmbH, Dimerix Limited, Goldfinch Bio Inc., Oraxion Therapeutics Inc., Variant Pharmaceuticals Inc.

What Are The Key Trends Of The Global Focal Segmental Glomerulosclerosis Market? Innovative Dual-Action Therapy Gains FDA Approval For Rare Kidney Disorder

Major companies operating in the focal segmental glomerulosclerosis market are focusing on developing innovative therapies such as non-immunosuppressive oral medication to improve patient outcomes and reduce treatment side effects. Non-immunosuppressive oral medication is a drug taken by mouth that treats disease without weakening the immune system, helping manage focal segmental glomerulosclerosis by targeting kidney damage directly while avoiding immune-related side effects. For instance, in May 2025, Travere Therapeutics Inc., a US-based biopharmaceutical company, received approval from the U.S. Food and Drug Administration (FDA) for its supplemental New Drug Application (sNDA) for FILSPARI (sparsentan), granting traditional approval for the treatment of focal segmental glomerulosclerosis (FSGS). FILSPARI is a first-in-class therapy that works by simultaneously blocking both the endothelin type A receptor (ETAR) and the angiotensin II type 1 receptor (AT1R). This dual mechanism significantly reduces proteinuria in conditions such as FSGS and IgA nephropathy. Compared to existing treatments, FILSPARI offers improved kidney protection while maintaining a strong safety profile.

What Are Latest Mergers And Acquisitions In The Focal Segmental Glomerulosclerosis Market? Novartis Acquires Chinook Therapeutics To Strengthen Rare Kidney Disease Portfolio

In August 2023, Novartis AG, a Switzerland-based pharmaceutical corporation, acquired Chinook Therapeutics Inc. for $3.5 billion. With this acquisition, Novartis aims to strengthen its position in rare kidney diseases by expanding its innovative pipeline with late-stage therapies for IgA nephropathy. Chinook Therapeutics Inc. is a US-based biotechnology company that is actively involved in the development of therapies for focal segmental glomerulosclerosis.

What Is The Regional Outlook For The Global Focal Segmental Glomerulosclerosis Market?

North America was the largest region in the focal segmental glomerulosclerosis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the focal segmental glomerulosclerosis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the focal segmental glomerulosclerosis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Focal Segmental Glomerulosclerosis Market?

The focal segmental glomerulosclerosis market consists of revenues earned by entities by providing services such as diagnostic testing, dialysis services, kidney transplant services, supportive care services, and medical imaging. The market value includes the value of related goods sold by the service provider or included within the service offering. The focal segmental glomerulosclerosis market also includes sales of calcineurin inhibitors, mycophenolate mofetil, rituximab, sparsentan, and diuretics. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What is the Market Assessment and Strategic Outlook for the Focal Segmental Glomerulosclerosis Industry?

The focal segmental glomerulosclerosis market research report is one of a series of new reports from The Business Research Company that cover focal segmental glomerulosclerosis market statistics, including the focal segmental glomerulosclerosis industry's global market size, regional shares, competitors with the focal segmental glomerulosclerosis market share, detailed focal segmental glomerulosclerosis market segments, market trends and opportunities, and any further data you may need to thrive in the focal segmental glomerulosclerosis market. This focal segmental glomerulosclerosis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Focal Segmental Glomerulosclerosis Market Report Forecast Analysis
Report AttributeDetails
Market Size Value In 2025 $1.57 billion
Revenue Forecast In 2034 $2.09 billion
Growth Rate CAGR of 7.3% from 2025 to 2034
Base Year For Estimation 2024
Actual Estimates/Historical Data 2019-2024
Forecast Period 2025 - 2029 - 2034
Market Representation Revenue in USD Billion and CAGR from 2025 to 2034
Segments Covered The focal segmental glomerulosclerosis market covered in this report is segmented –
1) By Disease Type: Primary Focal Segmental Glomerulosclerosis, Secondary Focal Segmental Glomerulosclerosis
2) By Treatment: Drug Therapy, Dialysis, Kidney Transplant, Other Treatments
3) By Drug Class: Immunosuppressants, Angiotensin Inhibitors, Corticosteroids
4) By Route Of Administration: Oral, Parenteral
5) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users Subsegments:
1) By Primary Focal Segmental Glomerulosclerosis: Idiopathic Focal Segmental Glomerulosclerosis, Genetic Or Familial Focal Segmental Glomerulosclerosis, Collapsing Variant, Tip Lesion Variant, Cellular Variant, Perihilar Variant
2) By Secondary Focal Segmental Glomerulosclerosis: Virus-Associated Focal Segmental Glomerulosclerosis, Drug-Induced Focal Segmental Glomerulosclerosis, Adaptive Or Compensatory Focal Segmental Glomerulosclerosis, Other Secondary Causes
Regional Scope Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. Additional countries that can be covered in the report are Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, Mexico, Chile, Argentina, Colombia, Peru, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Key Companies Profiled Pfizer Inc., Merck And Co. Inc., Sanofi S.A., Eli Lilly and Company, Boehringer Ingelheim GmbH, Astellas Pharma Inc., Vertex Pharmaceuticals Incorporated, Mallinckrodt ARD LLC, Kyowa Kirin Co. Ltd., Aurinia Pharmaceuticals Inc., Travere Therapeutics Inc., Eledon Pharmaceuticals Inc., ZyVersa Therapeutics Inc., Complexa Inc., Certa Therapeutics, Delta 4 GmbH, Dimerix Limited, Goldfinch Bio Inc., Oraxion Therapeutics Inc., Variant Pharmaceuticals Inc.
Customization ScopeRequest for Sample
Pricing And Purchase OptionsExplore Purchase Options

    Table Of Contents

    1. Executive Summary

    2. Focal Segmental Glomerulosclerosis Market Characteristics

    3. Focal Segmental Glomerulosclerosis Market Trends And Strategies

    4. Focal Segmental Glomerulosclerosis Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

    5. Global Focal Segmental Glomerulosclerosis Growth Analysis And Strategic Analysis Framework

    5.1. Global Focal Segmental Glomerulosclerosis PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

    5.2. Analysis Of End Use Industries

    5.3. Global Focal Segmental Glomerulosclerosis Market Growth Rate Analysis

    5.4. Global Focal Segmental Glomerulosclerosis Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)

    5.5. Global Focal Segmental Glomerulosclerosis Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)

    5.6. Global Focal Segmental Glomerulosclerosis Total Addressable Market (TAM)

    6. Focal Segmental Glomerulosclerosis Market Segmentation

    6.1. Global Focal Segmental Glomerulosclerosis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Primary Focal Segmental Glomerulosclerosis

    Secondary Focal Segmental Glomerulosclerosis

    6.2. Global Focal Segmental Glomerulosclerosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Drug Therapy

    Dialysis

    Kidney Transplant

    Other Treatments

    6.3. Global Focal Segmental Glomerulosclerosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Immunosuppressants

    Angiotensin Inhibitors

    Corticosteroids

    6.4. Global Focal Segmental Glomerulosclerosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Oral

    Parenteral

    6.5. Global Focal Segmental Glomerulosclerosis Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Hospitals

    Homecare

    Specialty Clinics

    Other Users

    6.6. Global Focal Segmental Glomerulosclerosis Market, Sub-Segmentation Of Primary Focal Segmental Glomerulosclerosis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Idiopathic Focal Segmental Glomerulosclerosis

    Genetic Or Familial Focal Segmental Glomerulosclerosis

    Collapsing Variant

    Tip Lesion Variant

    Cellular Variant

    Perihilar Variant

    6.7. Global Focal Segmental Glomerulosclerosis Market, Sub-Segmentation Of Secondary Focal Segmental Glomerulosclerosis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Virus-Associated Focal Segmental Glomerulosclerosis

    Drug-Induced Focal Segmental Glomerulosclerosis

    Adaptive Or Compensatory Focal Segmental Glomerulosclerosis

    Other Secondary Causes

    7. Focal Segmental Glomerulosclerosis Market Regional And Country Analysis

    7.1. Global Focal Segmental Glomerulosclerosis Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    7.2. Global Focal Segmental Glomerulosclerosis Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    8. Asia-Pacific Focal Segmental Glomerulosclerosis Market

    8.1. Asia-Pacific Focal Segmental Glomerulosclerosis Market Overview

    Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

    8.2. Asia-Pacific Focal Segmental Glomerulosclerosis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    8.3. Asia-Pacific Focal Segmental Glomerulosclerosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    8.4. Asia-Pacific Focal Segmental Glomerulosclerosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    9. China Focal Segmental Glomerulosclerosis Market

    9.1. China Focal Segmental Glomerulosclerosis Market Overview

    9.2. China Focal Segmental Glomerulosclerosis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

    9.3. China Focal Segmental Glomerulosclerosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

    9.4. China Focal Segmental Glomerulosclerosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

    10. India Focal Segmental Glomerulosclerosis Market

    10.1. India Focal Segmental Glomerulosclerosis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    10.2. India Focal Segmental Glomerulosclerosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    10.3. India Focal Segmental Glomerulosclerosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    11. Japan Focal Segmental Glomerulosclerosis Market

    11.1. Japan Focal Segmental Glomerulosclerosis Market Overview

    11.2. Japan Focal Segmental Glomerulosclerosis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    11.3. Japan Focal Segmental Glomerulosclerosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    11.4. Japan Focal Segmental Glomerulosclerosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    12. Australia Focal Segmental Glomerulosclerosis Market

    12.1. Australia Focal Segmental Glomerulosclerosis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    12.2. Australia Focal Segmental Glomerulosclerosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    12.3. Australia Focal Segmental Glomerulosclerosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    13. Indonesia Focal Segmental Glomerulosclerosis Market

    13.1. Indonesia Focal Segmental Glomerulosclerosis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    13.2. Indonesia Focal Segmental Glomerulosclerosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    13.3. Indonesia Focal Segmental Glomerulosclerosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    14. South Korea Focal Segmental Glomerulosclerosis Market

    14.1. South Korea Focal Segmental Glomerulosclerosis Market Overview

    14.2. South Korea Focal Segmental Glomerulosclerosis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    14.3. South Korea Focal Segmental Glomerulosclerosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    14.4. South Korea Focal Segmental Glomerulosclerosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    15. Western Europe Focal Segmental Glomerulosclerosis Market

    15.1. Western Europe Focal Segmental Glomerulosclerosis Market Overview

    15.2. Western Europe Focal Segmental Glomerulosclerosis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    15.3. Western Europe Focal Segmental Glomerulosclerosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    15.4. Western Europe Focal Segmental Glomerulosclerosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    16. UK Focal Segmental Glomerulosclerosis Market

    16.1. UK Focal Segmental Glomerulosclerosis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    16.2. UK Focal Segmental Glomerulosclerosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    16.3. UK Focal Segmental Glomerulosclerosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    17. Germany Focal Segmental Glomerulosclerosis Market

    17.1. Germany Focal Segmental Glomerulosclerosis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    17.2. Germany Focal Segmental Glomerulosclerosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    17.3. Germany Focal Segmental Glomerulosclerosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    18. France Focal Segmental Glomerulosclerosis Market

    18.1. France Focal Segmental Glomerulosclerosis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    18.2. France Focal Segmental Glomerulosclerosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    18.3. France Focal Segmental Glomerulosclerosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    19. Italy Focal Segmental Glomerulosclerosis Market

    19.1. Italy Focal Segmental Glomerulosclerosis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    19.2. Italy Focal Segmental Glomerulosclerosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    19.3. Italy Focal Segmental Glomerulosclerosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    20. Spain Focal Segmental Glomerulosclerosis Market

    20.1. Spain Focal Segmental Glomerulosclerosis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    20.2. Spain Focal Segmental Glomerulosclerosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    20.3. Spain Focal Segmental Glomerulosclerosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    21. Eastern Europe Focal Segmental Glomerulosclerosis Market

    21.1. Eastern Europe Focal Segmental Glomerulosclerosis Market Overview

    21.2. Eastern Europe Focal Segmental Glomerulosclerosis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    21.3. Eastern Europe Focal Segmental Glomerulosclerosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    21.4. Eastern Europe Focal Segmental Glomerulosclerosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    22. Russia Focal Segmental Glomerulosclerosis Market

    22.1. Russia Focal Segmental Glomerulosclerosis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    22.2. Russia Focal Segmental Glomerulosclerosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    22.3. Russia Focal Segmental Glomerulosclerosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    23. North America Focal Segmental Glomerulosclerosis Market

    23.1. North America Focal Segmental Glomerulosclerosis Market Overview

    23.2. North America Focal Segmental Glomerulosclerosis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    23.3. North America Focal Segmental Glomerulosclerosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    23.4. North America Focal Segmental Glomerulosclerosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    24. USA Focal Segmental Glomerulosclerosis Market

    24.1. USA Focal Segmental Glomerulosclerosis Market Overview

    24.2. USA Focal Segmental Glomerulosclerosis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    24.3. USA Focal Segmental Glomerulosclerosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    24.4. USA Focal Segmental Glomerulosclerosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    25. Canada Focal Segmental Glomerulosclerosis Market

    25.1. Canada Focal Segmental Glomerulosclerosis Market Overview

    25.2. Canada Focal Segmental Glomerulosclerosis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    25.3. Canada Focal Segmental Glomerulosclerosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    25.4. Canada Focal Segmental Glomerulosclerosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    26. South America Focal Segmental Glomerulosclerosis Market

    26.1. South America Focal Segmental Glomerulosclerosis Market Overview

    26.2. South America Focal Segmental Glomerulosclerosis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    26.3. South America Focal Segmental Glomerulosclerosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    26.4. South America Focal Segmental Glomerulosclerosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    27. Brazil Focal Segmental Glomerulosclerosis Market

    27.1. Brazil Focal Segmental Glomerulosclerosis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    27.2. Brazil Focal Segmental Glomerulosclerosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    27.3. Brazil Focal Segmental Glomerulosclerosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    28. Middle East Focal Segmental Glomerulosclerosis Market

    28.1. Middle East Focal Segmental Glomerulosclerosis Market Overview

    28.2. Middle East Focal Segmental Glomerulosclerosis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    28.3. Middle East Focal Segmental Glomerulosclerosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    28.4. Middle East Focal Segmental Glomerulosclerosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    29. Africa Focal Segmental Glomerulosclerosis Market

    29.1. Africa Focal Segmental Glomerulosclerosis Market Overview

    29.2. Africa Focal Segmental Glomerulosclerosis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    29.3. Africa Focal Segmental Glomerulosclerosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    29.4. Africa Focal Segmental Glomerulosclerosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    30. Focal Segmental Glomerulosclerosis Market Competitive Landscape And Company Profiles

    30.1. Focal Segmental Glomerulosclerosis Market Competitive Landscape

    30.2. Focal Segmental Glomerulosclerosis Market Company Profiles

    30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis

    30.2.2. Merck And Co. Inc. Overview, Products and Services, Strategy and Financial Analysis

    30.2.3. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis

    30.2.4. Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis

    30.2.5. Boehringer Ingelheim GmbH Overview, Products and Services, Strategy and Financial Analysis

    31. Focal Segmental Glomerulosclerosis Market Other Major And Innovative Companies

    31.1. Astellas Pharma Inc.

    31.2. Vertex Pharmaceuticals Incorporated

    31.3. Mallinckrodt ARD LLC

    31.4. Kyowa Kirin Co. Ltd.

    31.5. Aurinia Pharmaceuticals Inc.

    31.6. Travere Therapeutics Inc.

    31.7. Eledon Pharmaceuticals Inc.

    31.8. ZyVersa Therapeutics Inc.

    31.9. Complexa Inc.

    31.10. Certa Therapeutics

    31.11. Delta 4 GmbH

    31.12. Dimerix Limited

    31.13. Goldfinch Bio Inc.

    31.14. Oraxion Therapeutics Inc.

    31.15. Variant Pharmaceuticals Inc.

    32. Global Focal Segmental Glomerulosclerosis Market Competitive Benchmarking And Dashboard

    33. Key Mergers And Acquisitions In The Focal Segmental Glomerulosclerosis Market

    34. Recent Developments In The Focal Segmental Glomerulosclerosis Market

    35. Focal Segmental Glomerulosclerosis Market High Potential Countries, Segments and Strategies

    35.1 Focal Segmental Glomerulosclerosis Market In 2029 - Countries Offering Most New Opportunities

    35.2 Focal Segmental Glomerulosclerosis Market In 2029 - Segments Offering Most New Opportunities

    35.3 Focal Segmental Glomerulosclerosis Market In 2029 - Growth Strategies

    35.3.1 Market Trend Based Strategies

    35.3.2 Competitor Strategies

    36. Appendix

    36.1. Abbreviations

    36.2. Currencies

    36.3. Historic And Forecast Inflation Rates

    36.4. Research Inquiries

    36.5. The Business Research Company

    36.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2019-2024, $ Billion
  • Table 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion
  • Table 3: Global Focal Segmental Glomerulosclerosis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 4: Global Focal Segmental Glomerulosclerosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 5: Global Focal Segmental Glomerulosclerosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 6: Global Focal Segmental Glomerulosclerosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 7: Global Focal Segmental Glomerulosclerosis Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 8: Global Focal Segmental Glomerulosclerosis Market, Sub-Segmentation Of Primary Focal Segmental Glomerulosclerosis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 9: Global Focal Segmental Glomerulosclerosis Market, Sub-Segmentation Of Secondary Focal Segmental Glomerulosclerosis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 10: Global Focal Segmental Glomerulosclerosis Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 11: Global Focal Segmental Glomerulosclerosis Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 12: Asia-Pacific, Focal Segmental Glomerulosclerosis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 13: Asia-Pacific, Focal Segmental Glomerulosclerosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 14: Asia-Pacific, Focal Segmental Glomerulosclerosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 15: China, Focal Segmental Glomerulosclerosis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 16: China, Focal Segmental Glomerulosclerosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 17: China, Focal Segmental Glomerulosclerosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 18: India, Focal Segmental Glomerulosclerosis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 19: India, Focal Segmental Glomerulosclerosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 20: India, Focal Segmental Glomerulosclerosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 21: Japan, Focal Segmental Glomerulosclerosis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 22: Japan, Focal Segmental Glomerulosclerosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 23: Japan, Focal Segmental Glomerulosclerosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 24: Australia, Focal Segmental Glomerulosclerosis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 25: Australia, Focal Segmental Glomerulosclerosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 26: Australia, Focal Segmental Glomerulosclerosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 27: Indonesia, Focal Segmental Glomerulosclerosis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 28: Indonesia, Focal Segmental Glomerulosclerosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 29: Indonesia, Focal Segmental Glomerulosclerosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 30: South Korea, Focal Segmental Glomerulosclerosis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 31: South Korea, Focal Segmental Glomerulosclerosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 32: South Korea, Focal Segmental Glomerulosclerosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 33: Western Europe, Focal Segmental Glomerulosclerosis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 34: Western Europe, Focal Segmental Glomerulosclerosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 35: Western Europe, Focal Segmental Glomerulosclerosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 36: UK, Focal Segmental Glomerulosclerosis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 37: UK, Focal Segmental Glomerulosclerosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 38: UK, Focal Segmental Glomerulosclerosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 39: Germany, Focal Segmental Glomerulosclerosis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 40: Germany, Focal Segmental Glomerulosclerosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 41: Germany, Focal Segmental Glomerulosclerosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 42: France, Focal Segmental Glomerulosclerosis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 43: France, Focal Segmental Glomerulosclerosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 44: France, Focal Segmental Glomerulosclerosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 45: Italy, Focal Segmental Glomerulosclerosis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 46: Italy, Focal Segmental Glomerulosclerosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 47: Italy, Focal Segmental Glomerulosclerosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 48: Spain, Focal Segmental Glomerulosclerosis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 49: Spain, Focal Segmental Glomerulosclerosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 50: Spain, Focal Segmental Glomerulosclerosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 51: Eastern Europe, Focal Segmental Glomerulosclerosis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 52: Eastern Europe, Focal Segmental Glomerulosclerosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 53: Eastern Europe, Focal Segmental Glomerulosclerosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 54: Russia, Focal Segmental Glomerulosclerosis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 55: Russia, Focal Segmental Glomerulosclerosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 56: Russia, Focal Segmental Glomerulosclerosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 57: North America, Focal Segmental Glomerulosclerosis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 58: North America, Focal Segmental Glomerulosclerosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 59: North America, Focal Segmental Glomerulosclerosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 60: USA, Focal Segmental Glomerulosclerosis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 61: USA, Focal Segmental Glomerulosclerosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 62: USA, Focal Segmental Glomerulosclerosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 63: Canada, Focal Segmental Glomerulosclerosis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 64: Canada, Focal Segmental Glomerulosclerosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 65: Canada, Focal Segmental Glomerulosclerosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 66: South America, Focal Segmental Glomerulosclerosis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 67: South America, Focal Segmental Glomerulosclerosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 68: South America, Focal Segmental Glomerulosclerosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 69: Brazil, Focal Segmental Glomerulosclerosis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 70: Brazil, Focal Segmental Glomerulosclerosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 71: Brazil, Focal Segmental Glomerulosclerosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 72: Middle East, Focal Segmental Glomerulosclerosis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 73: Middle East, Focal Segmental Glomerulosclerosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 74: Middle East, Focal Segmental Glomerulosclerosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 75: Africa, Focal Segmental Glomerulosclerosis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 76: Africa, Focal Segmental Glomerulosclerosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 77: Africa, Focal Segmental Glomerulosclerosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 78: Pfizer Inc. Financial Performance
  • Table 79: Merck And Co. Inc. Financial Performance
  • Table 80: Sanofi S.A. Financial Performance
  • Table 81: Eli Lilly and Company Financial Performance
  • Table 82: Boehringer Ingelheim GmbH Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2019-2024, $ Billion
  • Figure 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion
  • Figure 3: Global Focal Segmental Glomerulosclerosis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 4: Global Focal Segmental Glomerulosclerosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 5: Global Focal Segmental Glomerulosclerosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 6: Global Focal Segmental Glomerulosclerosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 7: Global Focal Segmental Glomerulosclerosis Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 8: Global Focal Segmental Glomerulosclerosis Market, Sub-Segmentation Of Primary Focal Segmental Glomerulosclerosis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 9: Global Focal Segmental Glomerulosclerosis Market, Sub-Segmentation Of Secondary Focal Segmental Glomerulosclerosis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 10: Global Focal Segmental Glomerulosclerosis Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 11: Global Focal Segmental Glomerulosclerosis Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 12: Asia-Pacific, Focal Segmental Glomerulosclerosis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 13: Asia-Pacific, Focal Segmental Glomerulosclerosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 14: Asia-Pacific, Focal Segmental Glomerulosclerosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 15: China, Focal Segmental Glomerulosclerosis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 16: China, Focal Segmental Glomerulosclerosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 17: China, Focal Segmental Glomerulosclerosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 18: India, Focal Segmental Glomerulosclerosis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 19: India, Focal Segmental Glomerulosclerosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 20: India, Focal Segmental Glomerulosclerosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 21: Japan, Focal Segmental Glomerulosclerosis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 22: Japan, Focal Segmental Glomerulosclerosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 23: Japan, Focal Segmental Glomerulosclerosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 24: Australia, Focal Segmental Glomerulosclerosis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 25: Australia, Focal Segmental Glomerulosclerosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 26: Australia, Focal Segmental Glomerulosclerosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 27: Indonesia, Focal Segmental Glomerulosclerosis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 28: Indonesia, Focal Segmental Glomerulosclerosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 29: Indonesia, Focal Segmental Glomerulosclerosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 30: South Korea, Focal Segmental Glomerulosclerosis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 31: South Korea, Focal Segmental Glomerulosclerosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 32: South Korea, Focal Segmental Glomerulosclerosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 33: Western Europe, Focal Segmental Glomerulosclerosis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 34: Western Europe, Focal Segmental Glomerulosclerosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 35: Western Europe, Focal Segmental Glomerulosclerosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 36: UK, Focal Segmental Glomerulosclerosis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 37: UK, Focal Segmental Glomerulosclerosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 38: UK, Focal Segmental Glomerulosclerosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 39: Germany, Focal Segmental Glomerulosclerosis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 40: Germany, Focal Segmental Glomerulosclerosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 41: Germany, Focal Segmental Glomerulosclerosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 42: France, Focal Segmental Glomerulosclerosis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 43: France, Focal Segmental Glomerulosclerosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 44: France, Focal Segmental Glomerulosclerosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 45: Italy, Focal Segmental Glomerulosclerosis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 46: Italy, Focal Segmental Glomerulosclerosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 47: Italy, Focal Segmental Glomerulosclerosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 48: Spain, Focal Segmental Glomerulosclerosis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 49: Spain, Focal Segmental Glomerulosclerosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 50: Spain, Focal Segmental Glomerulosclerosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 51: Eastern Europe, Focal Segmental Glomerulosclerosis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 52: Eastern Europe, Focal Segmental Glomerulosclerosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 53: Eastern Europe, Focal Segmental Glomerulosclerosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 54: Russia, Focal Segmental Glomerulosclerosis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 55: Russia, Focal Segmental Glomerulosclerosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 56: Russia, Focal Segmental Glomerulosclerosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 57: North America, Focal Segmental Glomerulosclerosis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 58: North America, Focal Segmental Glomerulosclerosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 59: North America, Focal Segmental Glomerulosclerosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 60: USA, Focal Segmental Glomerulosclerosis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 61: USA, Focal Segmental Glomerulosclerosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 62: USA, Focal Segmental Glomerulosclerosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 63: Canada, Focal Segmental Glomerulosclerosis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 64: Canada, Focal Segmental Glomerulosclerosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 65: Canada, Focal Segmental Glomerulosclerosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 66: South America, Focal Segmental Glomerulosclerosis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 67: South America, Focal Segmental Glomerulosclerosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 68: South America, Focal Segmental Glomerulosclerosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 69: Brazil, Focal Segmental Glomerulosclerosis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 70: Brazil, Focal Segmental Glomerulosclerosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 71: Brazil, Focal Segmental Glomerulosclerosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 72: Middle East, Focal Segmental Glomerulosclerosis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 73: Middle East, Focal Segmental Glomerulosclerosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 74: Middle East, Focal Segmental Glomerulosclerosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 75: Africa, Focal Segmental Glomerulosclerosis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 76: Africa, Focal Segmental Glomerulosclerosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 77: Africa, Focal Segmental Glomerulosclerosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 78: Pfizer Inc. Financial Performance
  • Figure 79: Merck And Co. Inc. Financial Performance
  • Figure 80: Sanofi S.A. Financial Performance
  • Figure 81: Eli Lilly and Company Financial Performance
  • Figure 82: Boehringer Ingelheim GmbH Financial Performance
View Report
View Report
View Report
View Report
View Report
View Report
View Report
View Report

Frequently Asked Questions

What is the definition of the Focal Segmental Glomerulosclerosis market?

Focal segmental glomerulosclerosis (FSGS) is a rare kidney disorder marked by scarring (sclerosis) in segments of some glomeruli, the kidney’s filtering units, resulting in proteinuria and progressive kidney damage. It plays a key role in clinical diagnosis and research aimed at understanding proteinuria-related kidney diseases and developing targeted therapies to prevent kidney failure. For further insights on the Focal Segmental Glomerulosclerosis market, request a sample here

How will the Focal Segmental Glomerulosclerosis market drivers and restraints affect the market dynamics? What forces will shape the Focal Segmental Glomerulosclerosis industry going forward?

The Focal Segmental Glomerulosclerosis market major growth driver - The Rise In Kidney Diseases Fuels The Growth Of The Market Due To Increasing Incidence From Diabetes And CKD Mortality Trends. For further insights on the Focal Segmental Glomerulosclerosis market, request a sample here

What is the forecast market size or the forecast market value of the Focal Segmental Glomerulosclerosis market?

The Focal Segmental Glomerulosclerosis market size has grown strongly in recent years. The focal segmental glomerulosclerosis market size has grown strongly in recent years. It will grow from $1.46 billion in 2024 to $1.57 billion in 2025 at a compound annual growth rate (CAGR) of 7.6%. The growth in the historic period can be attributed to increasing prevalence of chronic kidney diseases, rising awareness about kidney disorders, increasing incidence of end-stage renal disease, increasing investment in research and development, and rising geriatric population. The focal segmental glomerulosclerosis market size is expected to see strong growth in the next few years. It will grow to $2.09 billion in 2029 at a compound annual growth rate (CAGR) of 7.3%. The growth in the forecast period can be attributed to a growing number of clinical trials, increasing healthcare infrastructure improvements, rising demand for personalized medicine, growing availability and accessibility of immunosuppressive drugs, and rising demand for tailored therapeutic interventions. Major trends in the forecast period include advancements in genetic research, integration of precision medicine, technology innovations in diagnostic tools, developments in immunosuppressive drug formulations, and advancements in biomarker identification. For further insights on the Focal Segmental Glomerulosclerosis market, request a sample here

How is the Focal Segmental Glomerulosclerosis market segmented?

The focal segmental glomerulosclerosis market covered in this report is segmented –
1) By Disease Type: Primary Focal Segmental Glomerulosclerosis, Secondary Focal Segmental Glomerulosclerosis
2) By Treatment: Drug Therapy, Dialysis, Kidney Transplant, Other Treatments
3) By Drug Class: Immunosuppressants, Angiotensin Inhibitors, Corticosteroids
4) By Route Of Administration: Oral, Parenteral
5) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users

Subsegments:
1) By Primary Focal Segmental Glomerulosclerosis: Idiopathic Focal Segmental Glomerulosclerosis, Genetic Or Familial Focal Segmental Glomerulosclerosis, Collapsing Variant, Tip Lesion Variant, Cellular Variant, Perihilar Variant
2) By Secondary Focal Segmental Glomerulosclerosis: Virus-Associated Focal Segmental Glomerulosclerosis, Drug-Induced Focal Segmental Glomerulosclerosis, Adaptive Or Compensatory Focal Segmental Glomerulosclerosis, Other Secondary Causes For further insights on the Focal Segmental Glomerulosclerosis market,
request a sample here

Which region has the largest share of the Focal Segmental Glomerulosclerosis market? What are the other regions covered in the report?

North America was the largest region in the focal segmental glomerulosclerosis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the focal segmental glomerulosclerosis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. For further insights on the Focal Segmental Glomerulosclerosis market, request a sample here.

Who are the major players in the Focal Segmental Glomerulosclerosis market?

Major companies operating in the focal segmental glomerulosclerosis market are Pfizer Inc., Merck And Co. Inc., Sanofi S.A., Eli Lilly and Company, Boehringer Ingelheim GmbH, Astellas Pharma Inc., Vertex Pharmaceuticals Incorporated, Mallinckrodt ARD LLC, Kyowa Kirin Co. Ltd., Aurinia Pharmaceuticals Inc., Travere Therapeutics Inc., Eledon Pharmaceuticals Inc., ZyVersa Therapeutics Inc., Complexa Inc., Certa Therapeutics, Delta 4 GmbH, Dimerix Limited, Goldfinch Bio Inc., Oraxion Therapeutics Inc., Variant Pharmaceuticals Inc. . For further insights on the Focal Segmental Glomerulosclerosis market, request a sample here.

What are the key trends in the Focal Segmental Glomerulosclerosis market?

Major trends in the Focal Segmental Glomerulosclerosis market include Innovative Dual-Action Therapy Gains FDA Approval For Rare Kidney Disorder. For further insights on the Focal Segmental Glomerulosclerosis market, request a sample here.

What are the major opportunities in the Focal Segmental Glomerulosclerosis market? What are the strategies for the Focal Segmental Glomerulosclerosis market?

For detailed insights on the major opportunities and strategies in the Focal Segmental Glomerulosclerosis market, request a sample here.

How does the Focal Segmental Glomerulosclerosis market relate to the overall economy and other similar markets?

For detailed insights on Focal Segmental Glomerulosclerosis's relation to the overall economy and other similar markets, request a sample here.

What are the latest mergers and acquisitions in the Focal Segmental Glomerulosclerosis industry?

For detailed insights on the mergers and acquisitions in the Focal Segmental Glomerulosclerosis industry, request a sample here.

What are the key dynamics influencing the Focal Segmental Glomerulosclerosis market growth? SWOT analysis of the Focal Segmental Glomerulosclerosis market.

For detailed insights on the key dynamics influencing the Focal Segmental Glomerulosclerosis market growth and SWOT analysis of the Focal Segmental Glomerulosclerosis industry, request a sample here.

Back to top
Back to top